Last reviewed · How we verify

Enamel Matrix Protein

T.C. Dumlupınar Üniversitesi · FDA-approved active Small molecule Quality 2/100

Enamel Matrix Protein is a Small molecule drug developed by T.C. Dumlupınar Üniversitesi. It is currently FDA-approved. Also known as: emdogain.

At a glance

Generic nameEnamel Matrix Protein
Also known asemdogain
SponsorT.C. Dumlupınar Üniversitesi
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Enamel Matrix Protein

What is Enamel Matrix Protein?

Enamel Matrix Protein is a Small molecule drug developed by T.C. Dumlupınar Üniversitesi.

Who makes Enamel Matrix Protein?

Enamel Matrix Protein is developed and marketed by T.C. Dumlupınar Üniversitesi (see full T.C. Dumlupınar Üniversitesi pipeline at /company/t-c-dumlup-nar-niversitesi).

Is Enamel Matrix Protein also known as anything else?

Enamel Matrix Protein is also known as emdogain.

What development phase is Enamel Matrix Protein in?

Enamel Matrix Protein is FDA-approved (marketed).

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing